Sign in

Gautam

Research Analyst at Leo Capital

Gautam is an Operations Analyst at Leo Capital, focusing on strategic research, marketing, platform development, stakeholder engagement, and event coordination within the investment team. He specializes in process integration and data-driven research, supporting key initiatives for the firm's operations. Gautam began his career at the University of Manchester and joined Leo Capital after making significant contributions in diversity, equity, and inclusion (DEI) and digital platform management. He holds credentials in business psychology and applies his expertise to institutional policy research, but no specific securities licenses or FINRA registrations are publicly listed at this time.

Gautam's questions to DR REDDYS LABORATORIES (RDY) leadership

Question · Q2 2026

Gautam asked about the company's GLP-1 strategy, specifically regarding API manufacturing capacity for Semaglutide and Liraglutide, target markets, and the status and capacity of fill-and-finish operations.

Answer

CEO Erez Israeli confirmed CTO6 manufactures API for GLP-1s and other peptides, with potential capacity up to 800 kg, targeting relevant markets including future Tirzepatide submissions. He reiterated 12 million pens for Semaglutide with a partner, and two cartridge lines in FQ11 (up to 50 million capacity) are being prepared for post-next 12 months.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts